Introduction: Alternative methods of dry storage and transportation may be a viable alternative to the use of liquid storage medium for cervical samples, especially for screening programs in places with few resources. Objective: The objective of this study is to verify the viability and efficacy of human papillomavirus DNA (HPV-DNA) detection in cervical cell samples collected and stored on a Flinders Technology Associates (FTA) card (Whatman Indicating FTA® Elute Micro Card) and subsequently recovered in ethanol-based liquid medium and to compare the results to those obtained using samples stored directly in ethanol-based liquid medium. Study Design: Thirty-four women submitted to ETZ (excision of the transformation zone of the cervix) were included in this study. Before ETZ, 2 samples of exfoliated cervical cells were collected from each woman by a doctor and stored in ethanol-based liquid medium and on an FTA card. DNA recovery from FTA samples was performed using ethanol-based liquid medium. Detection of HPV-DNA in the samples was performed using the Cobas® 4800 HPV Test Platform. Results and Conclusions: The HPV-DNA detection positivity rates were 70.6% for the samples collected directly in liquid medium and 64.7% for the samples stored on the FTA card, with high detection accuracy in the DNA samples recovered from the FTA card (area under the curve = 0.958; 95% confidence interval = 0.890–1.000). The concordance between the results obtained using the 2 storage media was 94.1% (Kappa = 0.866). These preliminary results suggest that collection of cervical material on an FTA card may be an alternative to storage in liquid medium since the liquid medium has some limitations. In addition, DNA recovery from the card using ethanol-based liquid medium streamlines the workflow in the laboratory and reduces the cost associated with reagents, thereby facilitating access to the HPV test in places with few resources and potentially improving cervical cancer screening.

1.
Bray
F
,
Ferlay
J
,
Soerjomataram
I
,
Siegel
RL
,
Torre
LA
,
Jemal
A
.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
.
CA Cancer J Clin
.
2018
;
68
(
6
):
394
424
. .
2.
Ferlay
J
,
Colombet
M
,
Soerjomataram
I
,
Mathers
C
,
Parkin
DM
,
Piñeros
M
, et al
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
.
Int J Cancer
.
2019
;
144
(
8
):
1941
53
. .
3.
Walboomers
JM
,
Jacobs
MV
,
Manos
MM
,
Bosch
FX
,
Kummer
JA
,
Shah
KV
, et al
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
.
J Pathol
.
1999
;
189
(
1
):
12
9
. .
4.
Goel
A
,
Gandhi
G
,
Batra
S
,
Bhambhani
S
,
Zutshi
V
,
Sachdeva
P
.
Visual inspection of the cervix with acetic acid for cervical intraepithelial lesions
.
Int J Gynaecol Obstet
.
2005
;
88
(
1
):
25
30
. .
5.
Hegde
D
,
Shetty
H
,
Shetty
PK
,
Rai
S
.
Diagnostic value of acetic acid comparing with conventional pap smear in the detection of colposcopic biopsy-proved CIN
.
J Cancer Res Ther
.
2011
;
7
(
4
):
454
8
. .
6.
Bedell
SL
,
Goldstein
LS
,
Goldstein
AR
,
Goldstein
AT
.
Cervical cancer screening: past, present, and future
.
Sex Med Rev
.
2020
;
8
(
1
):
28
37
. .
7.
Sankaranarayanan
R
,
Nene
BM
,
Shastri
SS
,
Jayant
K
,
Muwonge
R
,
Budukh
AM
, et al
HPV screening for cervical cancer in rural India
.
N Engl J Med
.
2009
;
360
(
14
):
1385
94
. .
8.
Ying
H
,
Jing
F
,
Fanghui
Z
,
Youlin
Q
,
Yali
H
.
High-risk HPV nucleic acid detection kit-the careHPV test –a new detection method for screening
.
Sci Rep
.
2014
;
4
:
4704
. .
9.
Wright
TC
,
Stoler
MH
,
Behrens
CM
,
Sharma
A
,
Zhang
G
,
Wright
TL
.
Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test
.
Gynecol Oncol
.
2015
;
136
(
2
):
189
97
. .
10.
Guido
R
.
Cervical Cancer Screening
.
Clin Obstet Gynecol
.
2018
;
61
(
1
):
40
51
. .
11.
Cuzick
J
,
Arbyn
M
,
Sankaranarayanan
R
,
Tsu
V
,
Ronco
G
,
Mayrand
MH
, et al
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries
.
Vaccine
.
2008
;
26
(
Suppl 10
):
K29
41
. .
12.
USPST Force
,
Curry
SJ
,
Krist
AH
,
Owens
DK
,
Barry
MJ
,
Caughey
AB
, et al
Screening for cervical cancer: US preventive services task force recommendation statement
.
JAMA
.
2018
;
320
(
7
):
674
86
. .
13.
Ketelaars
PJW
,
Bosgraaf
RP
,
Siebers
AG
,
Massuger
LFAG
,
van der Linden
JC
,
Wauters
CAP
, et al
High-risk human papillomavirus detection in self-sampling compared to physician-taken smear in a responder population of the Dutch cervical screening: results of the VERA study
.
Prev Med
.
2017
;
101
:
96
101
. .
14.
Smith
M
,
Lew
JB
,
Simms
K
,
Canfell
K
.
Impact of HPV sample self-collection for underscreened women in the renewed cervical screening program
.
Med J Aust
.
2016
;
204
(
5
):
1941e
7
. .
15.
Virtanen
A
,
Anttila
A
,
Luostarinen
T
,
Malila
N
,
Nieminen
P
.
Improving cervical cancer screening attendance in Finland
.
Int J Cancer
.
2015
;
136
(
6
):
E677
84
. .
16.
Viviano
M
,
Catarino
R
,
Jeannot
E
,
Boulvain
M
,
Malinverno
MU
,
Vassilakos
P
, et al
Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial
.
Br J Cancer
.
2017
;
116
(
11
):
1382
8
. .
17.
Winer
R
,
Tiro
JA
,
Miglioretti
DL
,
Thayer
C
,
Beatty
T
,
Lin
J
, et al
Corrigendum to “Rationale and design of the HOME trial: apragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system”
.
Contemp Clin Trials
.
2019
;
84
:
105811
. .
18.
Sultana
F
,
Gertig
DM
,
Wrede
CD
,
English
DR
,
Simpson
JA
,
Drennan
KT
, et al
A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing
.
J Clin Virol
.
2015
;
69
:
210
3
. .
19.
Wang
SM
,
Hu
SY
,
Chen
W
,
Chen
F
,
Zhao
FH
,
He
W
, et al
Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening
.
BMC Cancer
.
2015
;
15
:
848
. .
20.
Luo
H
,
Du
H
,
Maurer
K
,
Belinson
JL
,
Wang
G
,
Liu
Z
, et al
An evaluation of the Cobas4800 HPV test on cervico-vaginal specimens in liquid versus solid transport media
.
PLoS One
.
2016
;
11
(
2
):
e0148168
. .
21.
Gustavsson
I
,
Lindell
M
,
Wilander
E
,
Strand
A
,
Gyllensten
U
.
Use of FTA card for dry collection, transportation and storage of cervical cell specimen to detect high-risk HPV
.
J Clin Virol
.
2009
;
46
(
2
):
112
6
. .
22.
de Bie
RP
,
Schmeink
CE
,
Bakkers
JM
,
Snijders
PJ
,
Quint
WG
,
Massuger
LF
, et al
The indicating FTA elute cartridge a solid sample carrier to detect high-risk HPV and high-grade cervical lesions
.
J Mol Diagn
.
2011
;
13
(
4
):
371
6
. .
23.
Gustavsson
I
,
Sanner
K
,
Lindell
M
,
Strand
A
,
Olovsson
M
,
Wikström
I
, et al
Type-specific detection of high-risk human papillomavirus (HPV) in self-sampled cervicovaginal cells applied to FTA elute cartridge
.
J Clin Virol
.
2011
;
51
(
4
):
255
8
. .
24.
Dong
L
,
Lin
C
,
Li
L
,
Wang
M
,
Cui
J
,
Feng
R
, et al
An evaluation of clinical performance of FTA cards for HPV 16/18 detection using cobas 4800 HPV test compared to dry swab and liquid medium
.
J Clin Virol
.
2017
;
94
:
67
71
. .
25.
Lindemann
ML
,
Dominguez
MJ
,
de Antonio
JC
,
Sandri
MT
,
Tricca
A
,
Sideri
M
, et al
Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes
.
J Mol Diagn
.
2012
;
14
(
1
):
65
70
. .
26.
F. Hoffmann-La Roche Ltd
.
Cobas® 4800 HPV test
. 2020 Sep 23. Available from: https://diagnostics.roche.com/global/en/products/params/cobas-hpv.html.
27.
Feng
Q
,
Cherne
S
,
Winer
RL
,
Popov
V
,
Zambrano
H
,
Yerovi
C
, et al
Evaluation of transported dry and wet cervical exfoliated samples for detection of human papillomavirus infection
.
J Clin Microbiol
.
2010
;
48
(
9
):
3068
72
. .
28.
Geraets
DT
,
van Baars
R
,
Alonso
I
,
Ordi
J
,
Torné
A
,
Melchers
WJ
, et al
Clinical evaluation of high-risk HPV detection on self-samples using the indicating FTA-elute solid-carrier cartridge
.
J Clin Virol
.
2013
;
57
(
2
):
125
9
. .
29.
Guan
Y
,
Gravitt
PE
,
Howard
R
,
Eby
YJ
,
Wang
S
,
Li
B
, et al
Agreement for HPV genotyping detection between self-collected specimens on a FTA cartridge and clinician-collected specimens
.
J Virol Methods
.
2013
;
189
(
1
):
167
71
. .
30.
Lenselink
CH
,
de Bie
RP
,
van Hamont
D
,
Bakkers
JM
,
Quint
WG
,
Massuger
LF
, et al
Detection and genotyping of human papillomavirus in self-obtained cervicovaginal samples by using the FTA cartridge: new possibilities for cervical cancer screening
.
J Clin Microbiol
.
2009
;
47
(
8
):
2564
70
. .
31.
Sciences GHL
.
Whatman FTA technology
.
2011 Sep
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.